Articles with public access mandates - Mansoor Raza Mirza - US National Institutes of HealthLearn more
NoteFor this mandate, articles should be available from specific locations.
Not available based on mandate: 5
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ...
Annals of oncology 33 (9), 860-877, 2022
Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary
NS Reed, E Gomez-Garcia, D Gallardo-Rincon, B Barrette, K Baumann, ...
International Journal of Gynecologic Cancer 24 (Supp 3), 2014
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
I Vergote, A Gonzalez-Martin, D Lorusso, C Gourley, MR Mirza, JE Kurtz, ...
The Lancet Oncology 23 (8), e374-e384, 2022
Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study
DK Gaffney, A Du Bois, K Narayan, N Reed, T Toita, S Pignata, P Blake, ...
International Journal of Gynecologic Cancer 19 (1), 2009
Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer
CS Vorbeck, A Jhingran, RB Iyer, A Loft, A Klopp, MR Mirza, ...
International Journal of Gynecologic Cancer 29 (5), 2019
Available based on mandate: 5
Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease
MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, ...
Annals of Oncology 28 (4), 727-732, 2017
First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors
AR Abdul Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, ...
Journal of Clinical Oncology 34 (34), 4142-4150, 2016
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
MR Stockler, F Hilpert, M Friedlander, MT King, L Wenzel, CK Lee, F Joly, ...
Journal of Clinical Oncology 32 (13), 1309-1316, 2014
MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
BJ Monk, RN Grisham, S Banerjee, E Kalbacher, MR Mirza, I Romero, ...
Journal of clinical oncology 38 (32), 3753-3762, 2020
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous …
MR Mirza, G Lindahl, S Mahner, A Redondo, M Fabbro, BJ Rimel, ...
Cancer research communications 2 (11), 1436-1444, 2022
Publication and funding information is determined automatically by a computer program